France's Inventiva H1 net loss narrows

Overview

• Net loss for H1 2026 narrowed to €69.5 mln from €175.9 mln in prior year

• Company increased R&D and G&A expenses, driven by clinical development and pre-commercial activities

Outlook

• Inventiva expects topline results from Phase 3 NATiV3 trial in Q4 2026

• Company maintains cash runway guidance to end of Q2 2027

• Cash runway could extend to early Q1 2028 if additional financing is secured

Result Drivers

• NO LICENSE REVENUE - Co recorded no revenue in H1 2026, as prior-year revenue was attributable to a licensing agreement with Chia Tai Tianging

• R&D SPENDING - Higher R&D expenses driven by clinical development of lanifibranor for MASH

• PRE-COMMERCIAL COSTS - Increased marketing and G&A expenses reflect preparations for potential commercial launch of lanifibranor

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Inventiva SA is €10.47, about 267.9% above its September 25 closing price of €2.85

Reuters Recommended Reads

• Sept 25 - ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO

• Sept 25 - US FDA approves Mirum's drug for rare bone disorder

• Sept 25 - Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)